Cue Biopharma CUE 深 沪
等待开盘 08-10 09:30:00 美东时间
27.12
+0.110
+0.41%
华盛通- 最 高28.46
- 今 开27.42
- 成交量 5.73万股
- 最 低 26.03
- 昨 收 27.01
- 总市值 95.93万
- 52周最高 45.50
- 市盈率 静 --
- 换手率 161.93%
- 52周最低 0.1657
- 委 比 -90.48%
- 总股本 3.54万
- 历史最高 45.50
- 量 比 0.24
- 振 幅 9.00%
- 历史最低 0.1657
- 每 手 1
- 风险率 12.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Market-Moving News for May 1st
AAPL: 4% | Apple shares are trading higher after the company reported better-than-expected Q2 financial results, issued Q3 sales guidance above estimates, announced a $100 billion share buyback, and raised its
05-01 19:16
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 76.7% to $0.18 du...
04-13 20:05
Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim
Cue Biopharma stock jumps after $7.5 million milestone from Boehringer Ingelheim, with additional milestone potential and pipeline progress.
04-11 02:45
【公益案例展】商汤“算电协同平台”——打造绿色算力基础设施用能新范式
（来源：数智猿） 该项目案例由商汤科技投递并参与数智猿×数据猿×上海大数据联盟共同推出的#技术向善·榜样的力量#《2025中国数智产业最具社会责任感企业...
2025-09-01 20:46
万春医药盘中异动 股价大涨6.83%
北京时间2024年09月28日03时15分，万春医药（BYSI.us）股票出现波动，股价急速上涨6.83%。截至发稿，该股报2.19美元/股，成交量2.2928万股，换手率0.06%，振幅6.34%。 最近的财报数据显示，该股实现营业收入1000000.00美元，净利润-7.26百万美元，每股收益-0.19美元，毛利--，市盈率-5.25倍。 机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。 万春医药股票所在的生物技术行业中，整体跌幅为1.10%。其相关个股中，Nls Pharmaceutics Ltd C/Wts 02/02/2026(To Pur Com)、Onconetix...
2024-09-28 03:15
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock increased by 16.8% to $0....
2024-09-27 04:31
Stifel Maintains Buy on Cue Biopharma, Lowers Price Target to $4
Stifel analyst Stephen Willey maintains Cue Biopharma (NASDAQ:CUE) with a Buy and lowers the price target from $8 to $4.
2024-08-20 19:36
Cue Biopharma Q2 Net Loss Narrows, Revenue Rises
05:23 PM EDT, 08/19/2024 (MT Newswires) -- Cue Biopharma (CUE) reported a Q2 net loss late Monday of $0.20 per diluted share, narrowing from a loss of $0.29 a year earlier. Four analysts polled by Capital IQ expected a loss of $0.27. Revenue for the quarter ended June 30 was $2.7 million, up from $1...
2024-08-20 05:23
Cue Biopharma Q2 2024 GAAP EPS $(0.20) Beats $(0.24) Estimate, Sales $2.658M Beat $1.293M Estimate
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.24) by 16.67 percent. The company reported quarterly sales of $2.658 million which beat the analyst consensus estimate of $1.293 million by 105.61 percent. This is a 92.33 perce...
2024-08-20 04:12
